Sir, Sickle-cell disease (SCD) is one of the most common severe monogenic disorders worldwide. Acute chest syndrome (ACS) is a major complication of SCD and a significant cause of morbidity and mortality in adult patients. ACS is characterized by fever and/or respiratory symptoms with new pulmonary infiltrates. Of the various triggering factors involved in the pathogenesis of ACS, bacterial infection was found to be a cause in 20% of ACS cases in a large series. 1 As our ability to distinguish between the different causes of ACS is usually challenging, the current guidelines recommend the use of antibiotics for the treatment of severe ACS. [2] [3] [4] In practice, empirical antimicrobial therapy for severe ACS is usually combination therapy with a b-lactam antibiotic and a macrolide. 2 In patients with SCD, glomerular hyperfiltration (defined as augmented renal clearance) is common 5, 6 and might result in subtherapeutic b-lactam concentrations. 7 We herein describe a prospective cohort of 32 patients with SCD who were admitted between 2016 and 2018 to the ICU of the Henri Mondor university hospital (Creteil, France) for severe ACS and empirically treated with b-lactam antibiotic therapy for suspected infection. b-Lactam antibiotics included either amoxicillin, with or without clavulanic acid (n " 2), or cefotaxime (n " 30) and were administered by intermittent infusion. No patient developed septic shock. The plasma concentrations of amoxicillin and cefotaxime were determined by a validated method using HPLC coupled with UV detection at 230 nm for amoxicillin and 260 nm for cefotaxime. 8 Internal and external quality controls were regularly performed. Blood samples were obtained just before infusion of the drug (trough concentrations) after at least the fourth dose had been received. The blactam pharmacokinetic/pharmacodynamic (PK/PD) target was considered achieved if the antibiotic trough concentration was .4-fold the MIC of amoxicillin/cefotaxime for Streptococcus pneumoniae (i.e. .2 mg/L). Glomerular filtration rate (eGFR) was estimated from serum creatinine by using the best method in adult patients with SCD, 5 i.e. the CKD-EPI equation without adjustment for ethnicity. Hyperfiltration was defined as eGFR 
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.110 mL/min/1.73 m 2 , as previously suggested for SCD patients. 5 The median (IQR) eGFR was 142 (126-153) mL/min/1.73 m 2 . Hyperfiltration was detected in the majority of patients (n " 26, 81%). The median (IQR) dose of b-lactam was 62 (48-87) mg/kg/day. The vast majority of patients (n " 27, 84%) presented undetectable (i.e. ,2 mg/L) trough concentrations. As compared with cases achieving the b-lactam PK/PD target, those with undetectable trough concentrations presented higher values of eGFR and more frequently a hyperfiltration state [ Figure 1 and Table S1 (available as Supplementary data at JAC Online)].
As previously described with vancomycin, 7 underdosing of b-lactams was common in patients with SCD in our series. Increased renal perfusion in patients with SCD may lead to augmented clearance of renally cleared antibiotics including b-lactams. Our results suggest the need for therapeutic drug monitoring of b-lactam antibiotics in patients with SCD, especially those with hyperfiltration. Therapeutic strategies including increased doses of antibiotics, continuous infusion and/or reduced tubular excretion of b-lactam by using probenecid could be implemented in order to achieve PK/PD targets in SCD patients treated with antibiotics. 9 
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